Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.26
↓-19% vs avg
5yr avg: 1.56
30Y Low1.2·High1.9
ROE
↑
-26.1%
↓+44% vs avg
5yr avg: -46.6%
30Y Low-65%·High-26%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CTNM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Contineum Therapeutics, Inc. Class A Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $443M | $317M | $379M | — | — | — |
| Enterprise Value | $376M | $249M | $363M | — | — | — |
| P/E Ratio → | -5.47 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 1.26 | 1.21 | 1.91 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CTNM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
CTNM Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -26.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | — | — |
| Operating Margin | — | — | — | -32.2% | — | — |
| Net Profit Margin | — | — | — | 45.4% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -26.1% | -26.1% | -64.9% | — | -48.1% | -47.1% |
| ROA | -24.5% | -24.5% | -24.6% | 25.1% | -40.0% | -41.1% |
| ROIC | -27.1% | -27.1% | -26.1% | -16.2% | -33.6% | — |
| ROCE | -29.0% | -29.0% | -31.1% | -19.1% | -41.3% | -42.9% |
CTNM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $76M exceeds total debt of $8M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | — | 0.15 | 0.08 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.26 | -0.08 | — | 0.01 | 0.00 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | 9.38 | — | — |
| Interest Coverage | — | — | — | 112.39 | -61.51 | -86.35 |
Net cash position: cash ($76M) exceeds total debt ($8M)
CTNM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Contineum Therapeutics, Inc. Class A Common Stock's current ratio of 27.50x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 23.29x to 27.50x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 27.50 | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Quick Ratio | 27.50 | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Cash Ratio | 26.98 | 26.98 | 20.53 | 22.83 | 6.26 | 18.78 |
| Asset Turnover | — | — | — | 0.38 | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
CTNM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Contineum Therapeutics, Inc. Class A Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $28M | $26M | $25M | $25M | $25M |
Peer Comparison
Compare CTNM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CTNMYou | $443M | -5.5 | — | — | — | — | -26.1% | -27.1% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ARQT | $3B | -189.2 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 TERN | $5B | -51.4 | — | — | — | — | -14.2% | -24.7% | — |
 ACAD | $4B | 9.3 | 25.5 | 34.8 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.8 | 6.7 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PTGX | $7B | -53.6 | — | 125.9 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 RXRX | $1B | -2.2 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
What if you invested $1,000 in CTNM 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in CTNM be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CTNM Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCTNM vs IMVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Immunovant, Inc..
Compare NowCTNM — Frequently Asked Questions
Quick answers to the most common questions about buying CTNM stock.
What is Contineum Therapeutics, Inc. Class A Common Stock's P/E ratio?
Contineum Therapeutics, Inc. Class A Common Stock's current P/E ratio is -5.5x. This places it at the 50th percentile of its historical range.
What is Contineum Therapeutics, Inc. Class A Common Stock's ROE?
Contineum Therapeutics, Inc. Class A Common Stock's return on equity (ROE) is -26.1%. The historical average is -46.6%.
Is CTNM stock overvalued?
Based on historical data, Contineum Therapeutics, Inc. Class A Common Stock is trading at a P/E of -5.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.